Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials

The efficacy and safety of lisdexamfetamine dimesylate (LDX) vs placebo in binge eating disorder (BED) was evaluated in two multicenter, double-blind, placebo-controlled trials. Adults (study 1, n=383; study 2, n=390) meeting DSM-IV-TR BED criteria were randomized (1:1) to placebo or LDX (50 or 70 m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuropsychopharmacology
Main Authors: McElroy, Susan L, Hudson, James, Ferreira-Cornwell, M Celeste, Radewonuk, Jana, Whitaker, Timothy, Gasior, Maria
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4793109/
https://ncbi.nlm.nih.gov/pubmed/26346638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2015.275
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares